Systematic literature review of the global burden of illness of mantle cell lymphoma

References

• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood. 1997;89(11):3909–3918.
   PubMed Web of Science ®Google Scholar
• Tiemann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol. 2005;131(1):29–38.
   PubMed Web of Science ®Google Scholar
• Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27(4):511–518.
   PubMed Web of Science ®Google Scholar
• Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558–565.
   PubMed Web of Science ®Google Scholar
• Hoster E, Rosenwald A, Berger F, et al. Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European mantle cell lymphoma network. J Clin Oncol. 2016;34(12):1386–1394.
   PubMed Web of Science ®Google Scholar
• Cohen JB, Han X, Jemal A, et al. Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma. Cancer. 2016;122(15):2356–2363.
   PubMed Web of Science ®Google Scholar
• Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27(8):1209–1213.
   PubMed Web of Science ®Google Scholar
• Chihara D, Cheah CY, Westin JR, et al. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol. 2016;172(1):80–88.
   PubMed Web of Science ®Google Scholar
• Campo E, Rule S. Mantle cell lymphoma: evolving management strategies. Blood. 2015;125(1):48–55.
   PubMed Web of Science ®Google Scholar
• Bernstein SH, Epner E, Unger JM, et al. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Ann Oncol. 2013;24(6):1587–1593.
   PubMed Web of Science ®Google Scholar
• Merli F, Luminari S, Ilariucci F, et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol. 2012;156(3):346–353.
   PubMed Web of Science ®Google Scholar
• Monga N, Nastoupil L, Garside J, et al. Burden of illness of follicular lymphoma and marginal zone lymphoma. Ann Hematol. 2019;98(1):175–183.
   PubMed Web of Science ®Google Scholar
• Aschebrook-Kilfoy B, Caces DBD, Ollberding NJ, et al. An upward trend in the age-specific incidence patterns for mantle cell lymphoma in the USA. Leuk Lymphoma. 2013;54(8):1677–1683.
   PubMed Web of Science ®Google Scholar
• Chihara D, Ito H, Matsuda T, et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol. 2014;164(4):536–545.
   PubMed Web of Science ®Google Scholar
• Liu L, Wang H, Chen Y, et al. Splenic marginal zone lymphoma: a population-based study on the 20012008 incidence and survival in the United States. Leuk Lymphoma. 2013;54(7):1380–1386.
   PubMed Web of Science ®Google Scholar
• Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443–459.
   PubMed Web of Science ®Google Scholar
• Smith A, Crouch S, Lax S, et al. Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK’s Haematological Malignancy Research Network. Br J Cancer. 2015;112(9):1575–1584.
   PubMed Web of Science ®Google Scholar
• Le Guyader-Peyrou S, Belot A, Maynadie M, et al. Cancer incidence in France over the 1980–2012 period: hematological malignancies. Revue D’Epidemiologie et de Sante Publique. 2016;64(2):103–112.
   PubMed Web of Science ®Google Scholar
• Issa DE, van de Schans SAM, Chamuleau MED, et al. Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989–2010. Haematologica. 2015;100(4):525–533.
   PubMed Web of Science ®Google Scholar
• Abrahamsson A, Albertsson-Lindblad A, Brown PN, et al. Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study. Blood. 2014;124(8):1288–1295.
   PubMed Web of Science ®Google Scholar
• Martin P, Maddocks K, Leonard JP, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127(12):1559–1563.
   PubMed Web of Science ®Google Scholar
• Migdady Y, Salhab M, Dang NH, et al. Disparities in conditional net survival among non-Hodgkin lymphoma survivors: a population-based analysis. Leuk Lymphoma. 2016;57(3):676–684.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ma S. Racial differences in mantle cell lymphoma in the United States. BMC Cancer. 2014;14(1):764.
   PubMed Web of Science ®Google Scholar
• Gill BS, Vargo JA, Pai SS, et al. Management trends and outcomes for stage I to II mantle cell lymphoma using the National Cancer Data Base: ascertaining the ideal treatment paradigm. Int J Radiat Oncol Biol Phys . 2015;93(3):668–676.
   PubMed Web of Science ®Google Scholar
• Bhatt VR, Loberiza FR, Smith LM, et al. Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: a Nebraska Lymphoma Study Group Experience. Leuk Lymphoma. 2016;57(6):1327–1334.
   PubMed Web of Science ®Google Scholar
• Chandran R, Gardiner SK, Simon M, et al. Survival trends in mantle cell lymphoma in the United States over 16 years 1992–2007. Leuk Lymphoma. 2012;53(8):1488–1493.
   PubMed Web of Science ®Google Scholar
• LaCasce AS, Vandergrift JL, Rodriguez MA, et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood. 2012;119(9):2093–2099.
   PubMed Web of Science ®Google Scholar
• Martin P, Chadburn A, Christos P, et al. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Ann Oncol. 2008;19(7):1327–1330.
   PubMed Web of Science ®Google Scholar
• Chihara D, Asano N, Ohmachi K, et al. Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan. Br J Haematol . 2015;170(5):657–668.
   PubMed Web of Science ®Google Scholar
• Kang BW, Sohn SK, Moon JH, et al. Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: study by the consortium for improving survival of lymphoma. Blood Res. 2014;49(1):15–21.
   PubMedGoogle Scholar
• Kimura Y, Sato K, Arakawa F, et al. Mantle cell lymphoma shows three morphological evolutions of classical, intermediate, and aggressive forms, which occur in parallel with increased labeling index of cyclin D1 and Ki-67. Cancer Sci. 2010;101(3):806–814.
   PubMed Web of Science ®Google Scholar
• Salek D, Vesela P, Boudova L, et al. Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database. Leuk Lymphoma. 2014;55(4):802–810.
   PubMed Web of Science ®Google Scholar
• Sarkozy C, Terre C, Jardin F, et al. Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index. Genes Chromosomes Cancer. 2014;53(1):106–116.
   PubMed Web of Science ®Google Scholar
• van de Schans SAM, van Steenbergen LN, Coebergh JWW, et al. Actual prognosis during follow-up of survivors of B-cell non-Hodgkin lymphoma in the Netherlands. Haematologica. 2014;99(2):339–345.
   PubMed Web of Science ®Google Scholar
• Griffiths R, Mikhael J, Gleeson M, et al. Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood. 2011;118(18):4808–4816.
   PubMed Web of Science ®Google Scholar
• Garcia-Noblejas A, Martinez Chamorro C, Navarro Matilla B, et al. Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience. Ann Hematol. 2014;93(9):1551–1558.
   PubMed Web of Science ®Google Scholar
• Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377(13):1250–1260.
   PubMed Web of Science ®Google Scholar
• Visco C, Tisi MC, Evangelista A, et al. Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. Br J Haematol. 2019;185(5):940–944.
   PubMed Web of Science ®Google Scholar
• Abrahamsson A, Dahle N, Jerkeman M. Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry. Leuk Lymphoma. 2011;52(10):1929–1935.
   PubMed Web of Science ®Google Scholar